Explained in 90 seconds
Increased demand for healthcare products/ DL due to rising share of the middle class
Above-average increase in healthcare spending in the Emerging Markets
Complementary building block for a diversified Emerging Markets portfolio
Indexed performance (as at: 18.10.2024)
NAV: USD 121.83 (17.10.2024)
Rolling performance (18.10.2024)
B-USD | MSCI Emerging Markets Healthcare Index | MSCI Emerging Markets Index | |
17.10.2023 - 17.10.2024 | -2.85% | 16.49% | 24.02% |
17.10.2022 - 17.10.2023 | 2.69% | 1.60% | 12.80% |
15.10.2021 - 17.10.2022 | -39.22% | -37.81% | -30.63% |
15.10.2020 - 15.10.2021 | -3.39% | 3.10% | 16.90% |
Annualized performance (18.10.2024)
B-USD | MSCI Emerging Markets Healthcare Index | MSCI Emerging Markets Index | |
1 year | -2.85% | 16.49% | 24.02% |
3 years | -15.36% | -9.80% | -1.17% |
5 years | -2.81% | 1.83% | 4.78% |
Since Inception p.a. | -0.35% | 0.34% | 4.35% |
Cumulative performance (18.10.2024)
B-USD | MSCI Emerging Markets Healthcare Index | MSCI Emerging Markets Index | |
1M | 0.20% | 3.18% | 5.45% |
YTD | -3.74% | 8.84% | 14.22% |
1 year | -2.85% | 16.49% | 24.02% |
3 years | -39.35% | -26.62% | -3.46% |
5 years | -13.27% | 9.47% | 26.27% |
Since Inception | -2.54% | 2.53% | 36.90% |
Annual performance
B-USD | MSCI Emerging Markets Healthcare Index | MSCI Emerging Markets Index | |
2023 | -8.24% | -1.29% | 9.83% |
2022 | -19.39% | -23.50% | -20.09% |
2021 | -22.96% | -19.82% | -2.54% |
2020 | 49.43% | 52.82% | 18.31% |
Facts & Key figures
Investment Focus
The fund’s aim is to achieve capital growth in the long term, is actively managed and invests in companies that have their registered office or carry out the majority of their economic activity in the healthcare markets of emerging countries. Its investment universe consists of generics producers, Show moreShow less
Investment suitability & Risk
Low risk
High risk
General Information
Investment Manager | Bellevue Asset Management AG |
Custodian | CACEIS BANK, LUXEMBOURG BRANCH |
Fund Administrator | CACEIS BANK, LUXEMBOURG BRANCH |
Auditor | PriceWaterhouseCoopers |
Launch date | 31.05.2017 |
Year end closing | 30. Jun |
NAV Calculation | Daily "Forward Pricing" |
Cut of time | 09:00 CET |
Management Fee | 1.60% |
Subscription Fee (max.) | 5.00% |
Performance Fee | 10.00% (with High Water Mark) |
ISIN number | LU1585228452 |
Valor number | 36153232 |
Bloomberg | BBAEMBU LX |
WKN | A2DPAU |
Total expense ratio (TER) | 2.23% (30.09.2024) |
Legal Information
Legal form | Luxembourg UCITS V SICAV |
SFDR category | Article 8 |
Redemption period | Daily |
Key data (30.09.2024, base currency USD)
Beta | 0.99 |
Volatility | 22.51 |
Tracking error | 9.49 |
Active share | 40.70 |
Correlation | 0.91 |
Sharpe ratio | -0.75 |
Information ratio | -0.55 |
Jensen's alpha | -4.89 |
No. of positions | 45 |
Portfolio
Top 10 positions
Market capitalization
Geographic breakdown
Breakdown by sector
Benefits & Risks
Benefits
- Access to defensive growth – emerging countries are facing aging populations and changing lifestyles.
- Development of healthcare infrastructure combined with a growing middle class is an additional growth driver.
- High growth potential of Emerging Markets.
- Attractive valuations compared with the projected medium to long-term growth.
- Bellevue Healthcare Team – top-performing pioneer in the management of healthcare portfolios in Emerging Markets.
Risks
- The fund actively invests in equities. Equities are subject to price fluctuations and so are also exposed to the risk of price losses.
- Investing in Emerging Markets entails the additional risk of political and social instability.
- The fund invests in foreign currencies, which means a corresponding degree of currency risk against the reference currency.
- The fund may invest in China A equities. This entails the risk of supervisory changes, volume caps and operating restrictions which may lead to a higher counterparty risk.
- The fund may invest a proportion of its assets in financial instruments that might under certain circumstances have a relatively low level of liquidity, which can in turn affect the fund’s liquidity.
Review / Outlook
In contrast to earlier government attempts to shore up Chinese capital markets and stabilize the economy, this time China’s leaders have crafted a broad stimulus package that includes monetary and fiscal policy measures that should provide some relief for households in particular. This is intended to lift household consumption and ease deflationary pressure. It appears that the Communist Party leadership has finally acknowledged that the situation is dramatic and that it must use every means at its disposal to fix it. President Xi Jinping recently spoke about the new policy stance in surprisingly frank terms. This represents a paradigm shift and could help to improve foreign investors’ confidence in China's capital markets. Besides lowering borrowing rates and providing relief for homeowners as well as support for the equity market, the package includes the equivalent of almost USD 450 bn for Chinese households. These measures range from tax cuts and government subsidies for household purchases of new cars and appliances to more generous unemployment benefits and cash handouts for young families and low-income households. The government forecasts that its fiscal deficit will rise above 3% of GDP as a result of the stimulus spending.
Chinese biotech company Akeso published groundbreaking Phase III data from its Chinese trial of ivonescimab, a bispecific antibody, in lung cancer patients. In a head-to-head comparison with Keytruda, the current standard of care, progression-free survival was more than 11 months compared to 5.8 months for Keytruda. This data has increased the likelihood that the international study being conducted by Akeso's partner Summit Therapeutics will also show a superior outcome. The fund is invested in both of these companies.
Last month existing fund positions in Akeso, Bangkok Dusit and Bumrungrad were increased and a new position in IPCA was opened. Positions in Summit, Dr. Reddy's, Divis and Aurobindo were reduced. Aier Eye Hospitals was removed from the portfolio.
Dokumente
Show moreShow less
ESG
These insights might interest you
I am happy to answer any questions you may have:
Senior Sales Germany
Alexander Jostes